Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and ...

This World Cancer Day, Pfizer Canada ULC ("Pfizer"), in partnership with leading oncology patient organizations, is proud to ...

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug ...

Shares of Danish obesity-drug maker Novo Nordisk plunged after it warned that it expects lower prices for Ozempic and Wegovy in the U.S. to weigh on 2026 sales, dragging them 5%-to-13% lower than 2025 ...

In lieu of a Super Bowl ad this year, Pfizer has unveiled a year-long cancer campaign that aims to encourage screening.

Pfizer Inc. Buy: market overreacts to Q4 loss and 2026 guidance; oncology-led growth, 102-candidate pipeline, and dividend offer upside. Click for this PFE update.

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

PF'3944 is an ultra-long-acting fully biased GLP-1 receptor agonist (RA). It is being developed as a single agent weekly and as a monthly therapy, and in combination with various peptides including an ...

The 2025-26 Pfizer COVID-19 vaccine is about 57% effective against emergency department/urgent care (ED/UC) visits and 54% ...

Pharmaceutical operations remain central to large-cap healthcare discussions Balance sheet positioning frames institutional comparisons Broader sentiment reflects themes seen in s&p 500 chart Pfizer ...

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.